Nonalcoholic fatty liver disease and nonalcoholic... : Liver Transplantation (original) (raw)
Original Articles: MANAGEMENT OF CHRONIC LIVER DISEASE
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
1Betty and Guy Beatty Center for Integrated Research, Inova Health SystemFalls ChurchVA
2Center for Liver Disease and Department of Medicine, Inova Fairfax HospitalFalls ChurchVA
*Address reprint requests to Zobair M. Younossi, M.D., M.P.H., F.A.A.S.L.D., Betty and Guy Beatty Center for Integrated Research, Inova Health System, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3300 Gallows Road, Falls Church, VA 22042. Telephone: 703‐776‐2540; FAX: 703‐776‐4386; E‐mail: [email protected]
Abstract
Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%.1 Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States.2 As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH.4 Therefore, the transplant team must be well versed in the state of current knowledge about NAFLD and transplant‐specific issues for this increasingly important indication for LT. Liver Transplantation 24 166–170 2018 AASLD.
© 2017 by the American Association for the Study of Liver Diseases.